secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALATIN TECHNOLOGIES INC (PTN)
CIK:        0000911216
Form:       8-K
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0001654954-23-015795
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palatin sells Vyleesi rights to Cosette for up to $171M; $12M upfront
---------------------------------------------------------------------

- Up-front payment of $12M plus sales-based milestones up to $159M based on annual net sales of $15M to $200M.
- Additional regulatory milestones of $10.5M from prior licenses (Fosun $7.5M, Kwangdong $3.0M) remain receivable.
- Palatin will provide transitional services; operational separation ensures continued patient access for Vyleesi.
- Company shifts focus to melanocortin pipeline: Phase 3 dry eye (PL9643) topline data expected soon; Phase 2 ulcerative colitis (PL8177) interim Q1 2024.
- Transaction closed simultaneously with signing on December 19, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/911216/000165495423015795/0001654954-23-015795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/911216/000165495423015795/ptn_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-015795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer